MeSH D002385 - cataplexy
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Avadel Pharmaceuticals | Oxybate | Lumryz | 2037-07-21 | 2023-05-01 | ||
| Hikma Pharmaceuticals | Oxybate | Oxybate | 2017-01-17 | |||
| Jazz Pharmaceuticals | Oxybate | Xyrem | 2022-12-17 | 2002-07-17 | $291.247 M | Q4/23-Q3/24 |
| Oxybate | Xywav | 2022-12-17 | 2020-07-21 | $1,409.257 M | Q4/23-Q3/24 | |
| UCB | Oxybate | Xyrem | 2005-10-13 |
Clinical Trials
Historical Success Rate
Phase 1
0%0/0
Phase 2
0%0/0
Phase 3
50%4/8
Approved: 4Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use